Company Description
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.
Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody.
The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023.
The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Sep 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 167 |
| CEO | Leon Moulder |
Contact Details
Address: 852 Winter Street, Suite 250 Waltham, Massachusetts 02451 United States | |
| Phone | 857 271 2954 |
| Website | zenasbio.com |
Stock Details
| Ticker Symbol | ZBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001953926 |
| CUSIP Number | 98937L105 |
| ISIN Number | US98937L1052 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leon Oliver Moulder Jr., M.B.A. | Founder, Chief Executive Officer and Chairman |
| Joseph L. Farmer | Chief Operating Officer and President |
| Dr. Lisa von Moltke M.D. | Head of Research and Development and Chief Medical Officer |
| Jennifer A. Fox | Chief Business Officer and Chief Financial Officer |
| Dr. Heinrich Schlieker Ph.D. | Chief Technical Officer |
| Dr. Haley Laken Ph.D. | Chief Scientific Officer |
| Caroline Chevalier | Chief Administrative Officer |
| Jeffrey Held | Chief Legal Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2026 | SCHEDULE 13D/A | Filing |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 30, 2026 | 424B5 | Filing |
| Mar 30, 2026 | 424B5 | Filing |
| Mar 27, 2026 | FWP | Free Writing Prospectus |
| Mar 27, 2026 | FWP | Free Writing Prospectus |
| Mar 26, 2026 | 424B5 | Filing |
| Mar 26, 2026 | 424B5 | Filing |
| Mar 26, 2026 | FWP | Free Writing Prospectus |
| Mar 16, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |